Construction and immunogenic properties of DNA vaccine against canine parvovirus infection

• Autorzy: Mizak B , Rzezutka A. , Krol J. , Kazula A.
• Języki publikacji: EN

Abstrakty

EN

The presented studies were concentrated on construction of the recombinant mammalian expression vector - pSecTag2B, carrying canine parvovirus VP2 gene and its N-terminal fragment. Evaluation of safety of experimental vaccines was done on laboratory animals and immunogenic properties were tested on dogs. CPV specific antibodies were not detected by HI test in serum samples collected from dogs vaccinated with recombinant plasmid pSecTag2B-CPV582. The presence of CPV specific antibodies (80-320 by HI) was confirmed 10 days after vaccination in all dogs vaccinated with pSecTag2B-CPV1774. The highest titre was obtained in sera collected from dogs vaccinated with 200 μg and 300 μg of DNA. Fourteen days after revaccination, the level of antibodies increased up to 160 in dogs vaccinated with 100 μg of DNA and up to 640 in puppies vaccinated with 200 μg and 300 μg of DNA. The antibodies were detected for at least 16 weeks. Results of the studies demonstrated the immunogenic properties of elaborated DNA vaccine.

Słowa kluczowe

EN

DNA vaccine; infection; Parvoviridae; dog; canine parvovirus; immunogenic property; animal disease

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2001
• Tom: 45
• Numer: 2
• Opis fizyczny: p.125-139,fig.

Twórcy

autor

Mizak B

• National Veterinary Research Institute, 24-100 Pulawy, Poland

autor

Rzezutka A.

autor

Krol J.

autor

Kazula A.

Bibliografia

• 1. Appel M., Scott F.W., Carmichael L.R.: Isolation and immunization studies of a canine parvovirus from dogs with haemorrhagic enteritis. Vet. Rec., 1985, 105, 156-159.
• 2. Bourne N., Stanberry L.R., Bernstein D.I., Lew D. : DNA immunization against experimental genital herpes simplex virus infection. J. lnfect. Dis., 1996, 173, 800-807.
• 3. Burtonboy G., Coignoul F., Delferriere N., Pastoret P.P.: Canine haemorrhagic enteritis: detection of viral particles by electron microscopy. Arch. Virol., 1979, 61, 1-11.
• 4. Carmichael L.E., Pollock R.V.H., Joubert J.C.: Response of puppies to canine - origin parvovirus vaccines. Med. Vet. Prac., 1984, 65, 99-102.
• 5. Cox G.J.M., Zamb T.J., Babjuk L.A.: Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol., 1993, 67, 5664-5667.
• 6. Chapek M.L., McClaughy L.E., Wilkins L.M.: Efficacy and safety of an inactivated panleukopenia virus vaccine against canine parvovirus infection. Mod. Vet. Prac., 1980, 61, 261-263.
• 7. Choi J.Y., Woo S.D., Lee H.K., Hong H.K., Je Y.H., Park J.H., Song J.Y., An S.H., Kang S.K.: High-level expression of canine parvovirus VP2 using Bombyx mori nucleopolyhedrovirus vector. Arch. Virol., 2000, 145, 171-177.
• 8. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H.: DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci., 1996, 93, 7213-7218.
• 9. Donelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S., Ulmer J.B., Liu M.A.: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med., 1995, 1, 583-587.
• 10. Donelly J.J., Ulmer J.B., Shiver J.W., Liu M.A.: DNA vaccines. Annu. Rev. Immunol., 1997, 15, 617-648.
• 11. Gil F., Brun A., Wigdorovitz A., Catala R., Martinez-Torrecuadrada, Casal J.I., Salinas J., Borca M.V., Escribano J.M.: High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Letters, 2001, 488, 13-17.
• 12. Górski J., Daniel A., Mizak B., Zwierzchowski J.: Requirements for haemagglutination inhibition test for diagnosis of parvovirus infection of carnivores. Bull. Vet. Inst. Pulawy, 1993, 38, 59-66.
• 13. Harlow E., Lane D.: Antibodies. A laboratory Mannual. Cold Spring Harbor Lab., New York 1988.
• 14. Jiang W., Baker H., Swango L.J., Schorr J., Self M.J., Smith B.F.: Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. Vaccine, 1998, 16, 601-607.
• 15. Langeveld J.P., Casal J.I., Vela C., Dalsgaard K., Smale S.H., Puijk W.C., Meloen R.H.: B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. J. Virol., 1993, 67, 765-772.
• 16. Langeveld J.P., Casal J.I., Osterhaus A.D.M.E., Cortes E., Sward R., Vela C., Dalsgaard K., Puijk W.C., Schaaper W.M.M., Meloen R.H.: First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J. Virol., 1994, 68, 4506-4513.
• 17. Langeveld J.P.M., Kamstrup S., Uttenthal A., Strandbygaard B., Vela C., Dalsgaard K., Beekman N.J.C.M., Meloen R.H., Casal J.I.: Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Vaccine, 1995, 13, 1033-1037.
• 18. Larson L.J., Schultz R.D.: Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. A.J.V.R., 1997, 58, 360-363 .
• 19. Lekutis C., Shiver J.W., Liu M.A., Letvin N.L.: HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4⁺ T helper cells that secrete IFN-γ and TNF-α. J. Immunol., 1997, 158, 4471-4477.
• 20. Lopez de Turiso J.A.L., Cortes E. Martinez C., Ybanez R.R., Simarro I., Vela C., Casal I: Recombinant vaccine for canine parvovirus in dogs. J. Virol., I 992, 66, 2748-2753.
• 21. Mizak B.: Konstrukcja rekombinowanej szczepionki przeciwko zakażeniom parwowirusowym zwierząt mięsożernych oraz ocena jej właściwości immunogennych. Rozprawa habilitacyjna, PIWet Puławy, 1996.
• 22. Mizak B., Borowski A.: Zastosowanie testu PLA do oceny namnażania wirusa nosówki, adenowirusa typu 1 oraz parwowirusa psów w hodowlach komórkowych. Medycyna Wet., 1998, 54, 753-756.
• 23. Paradiso P.R., Rhode S.L.III, Singer I.I.: Canine parvovirus: a biochemical and ultrastructural characterization. J. Gen. Virol., 1982, 62, 113-125.
• 24. Parrish C.R.: Emergence, natural history and variation of canine, mink and feline parvoviruses. Adv. Virus Res., 1990, 38, 403-50.
• 25. Pollock R.V.H., Carmichael L.E.: Maternally derived immunity to canine parvovirus infection: transfer, decline and interference with vaccination. J. Am. Vet. Med. Assoc., 1982, 180, 37-42.
• 26. Pollock R.V.H., Carmichael L.E.: Use of modified live feline panleukopenia virus vaccine to immunize dogs against canine parvovirus. Am. J. Vet. Res., 1983, 44, 169-175.
• 27. Ray N.B., Ewalt L.C., Lodmell D.L.: Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine, 1997, 8, 892-895.
• 28. Saliki J.T., Mizak B., Flore H.P., Getting R.R., Burand J.P., Carmichael L.E., Wood H.A., Parrish C.R.: Canine parvovirus capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J. Gen. Virol., 1993, 73, 369-374.
• 29. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L.: Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci., 1994, 91, 9866-9870.
• 30. Towbin H., Staehelin T., Gordon J.: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 1979, 76, 4350-4354.
• 31. Truyen U., Gruenberg A., Chang S.F., Obermaier B., Veijalainen P., Parrish C.P.: Evolution of the feline-subgroup parvovirus and the control of canine host range in vivo. J. Virol., 1995, 69, 4702- 4710.
• 32. Tsao J., Chapman M.S., Agbandje M., Keller W., Smith K., Wu H., Luo M., Smith T.J., Rossman M.G., Compans R.W., Parrish C.R.: The three-dimensional structure of canine parvovirus and its functional implications. Science, 1991, 251, 1456-1464.
• 33. Wang B., Ugen K.E., Srikantan V. Agadjanyan M.G., Dang K., Refaeli Y., Sato A.I., Boyer J., Williams W.V., Weiner D.B.: Gene inoculation generates immune response against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA, 1993, 90, 4156-4160.
• 34. Xiang Z.Q., Spitalnik S., Tran M., Wunner W.H., Cheng j., Ertl H.C.J.: Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology, 1994, 99, 132-140
• 35. Yamada O., Matsumoto T., Nakashima M., Hagari S., Kamahora T., Ueyama H., Kishi Y., Uemura H., Kurimura T.: A new method for extracting DNA or RNA for polymerase chain reaction. J. Virol. Meth., 1990, 27, 203-10.
• 36. Zhu X., Venkataprasad N., Thangaraj H.S., Hill M., Singh M., Ivanyi J., Vordermeier H.M.: Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J. Immunol., 1997, 158, 5921-5926.
• 37. Zurbriggen A., Schmit I., Tipold A., Fatzer R., Cordozo C., Schobesberger M., Griot M., Bruckner L., Vndavelde M., Cherpillod P., Wittek R.: Canine distemper: DNA vaccine studies. Canine Infectious Disease: From Clinics to Molecular Pathogenesis, Ithaca USA, August 1999. Proc. p. 29.